You are here

Roche

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Reuters

personalized medicine

Flag link:

Four New Drugs are Around the Corner. Here’s What You Need to Know.

Four New Drugs are Around the Corner. Here’s What You Need to Know.

Xconomy

Sarepta Therapeutics

Nabriva Therapeutics

Flag link:

Roche scores double cancer approval for new Bayer rival Rozlytrek

Roche scores double cancer approval for new Bayer rival Rozlytrek

Fierce Pharma

NTRK fusion-positive tumors

non-small cell lung cancer

Flag link:

Roche Expands Global Access to Viral Assays to Aid Eradication Efforts

Roche Expands Global Access to Viral Assays to Aid Eradication Efforts

Medical Devices and Diagnostics Industry

Global Access Program

Flag link:

Roche says test showed Tecentriq helped vs bladder cancer

Roche says test showed Tecentriq helped vs bladder cancer

Reuters

Flag link:

Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal

Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal

Endpoints

Flag link:

Go or no go? Abbvie, Roche and Kala await key decisions

Go or no go? Abbvie, Roche and Kala await key decisions

EP Vantage

Kala Pharmaceuticals

dry eye disease

Flag link:

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

Yahoo/Zacks.com

Flag link:

Roche axes early-phase inflammatory disease drug

Roche axes early-phase inflammatory disease drug

Fierce Biotech

inflammatory diseases

Flag link:

Roche, like Bayer, was hit in Winnti cyberattack

Roche, like Bayer, was hit in Winnti cyberattack

Fierce Pharma

Flag link:

Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza

Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza

Endpoints

Flag link:

Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market

Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market

Fierce Pharma

Flag link:

Roche and Novo Nordisk Top Clinical Trial Transparency Survey

Roche and Novo Nordisk Top Clinical Trial Transparency Survey

BioSpace

clinical trials

clinical trial transparency

Flag link:

Roche's Genentech goes on deal spree, unveiling third deal on the same day

Roche's Genentech goes on deal spree, unveiling third deal on the same day

Endpoints

Skyhawk Therapeutics

Convelo Therapeutics

Flag link:

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

Yahoo/Zacks.com

Flag link:

Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency

Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency

Fierce Pharma

pharma industry

clinical trial transparency

Flag link:

Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst

Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst

Fierce Pharma

Flag link:

Roche, Spark push back takeover deadline in $4.3 billion deal

Roche, Spark push back takeover deadline in $4.3 billion deal

Yahoo/Reuters

Spark Therapeutics

Flag link:

Roche’s flu drug Xofluza meets primary endpoint in phase III children study

Roche’s flu drug Xofluza meets primary endpoint in phase III children study

Pharmaceutical Business Review

clinical trials

Flag link:

Threats to Spinraza are mounting, but Biogen still has cards to play

Threats to Spinraza are mounting, but Biogen still has cards to play

EP Vantage

Flag link:

Pages